BioCentury
ARTICLE | Clinical News

MORAb-009: Phase II started

March 9, 2009 7:00 AM UTC

Eisai's Morphotek Inc. subsidiary began a single-arm, open-label, international Phase II trial (MORAb-009-003) to evaluate IV MORAb-009 given on days 1 and 8 of a 21-day cycle for 6 cycles plus pemet...